<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">MDM</journal-id>
<journal-id journal-id-type="hwp">spmdm</journal-id>
<journal-id journal-id-type="nlm-ta">Med Decis Making</journal-id>
<journal-title>Medical Decision Making</journal-title>
<issn pub-type="ppub">0272-989X</issn>
<issn pub-type="epub">1552-681X</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0272989X11398489</article-id>
<article-id pub-id-type="publisher-id">10.1177_0272989X11398489</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Use of a Catalytic Model to Estimate Hepatitis A Incidence in a Low-Endemicity Country</article-title>
<subtitle>Implications for Modeling Immunization Policies</subtitle>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Pham</surname><given-names>Ba’</given-names></name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Chen</surname><given-names>Maggie Hong</given-names></name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Tricco</surname><given-names>Andrea C.</given-names></name>
<degrees>PhD</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Anonychuk</surname><given-names>Andrea</given-names></name>
<degrees>MSc</degrees>
</contrib>
<contrib contrib-type="author">
<name><surname>Krahn</surname><given-names>Murray</given-names></name>
<degrees>MD</degrees>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Bauch</surname><given-names>Chris T.</given-names></name>
<degrees>PhD</degrees>
</contrib>
</contrib-group>
<aff id="aff1-0272989X11398489">Toronto Health Economics and Technology Assessment Collaborative, University of Toronto, Toronto, Ontario, Canada (BP, MK)</aff>
<aff id="aff2-0272989X11398489">Department of Health Policy, Management and Evaluation, University of Toronto (BP, MK)</aff>
<aff id="aff3-0272989X11398489">Department of Biostatistics, University of Toronto (MHC)</aff>
<aff id="aff4-0272989X11398489">Toronto General Hospital, University Health Network, Toronto (MHC)</aff>
<aff id="aff5-0272989X11398489">Li Ka Shing Knowledge Institute of St Michael’s Hospital, Toronto (ACT)</aff>
<aff id="aff6-0272989X11398489">Leslie Dan Faculty of Pharmacy, University of Toronto (AA, MK)</aff>
<aff id="aff7-0272989X11398489">GlaxoSmithKline Biologics, Rixensart, Belgium (AA)</aff>
<aff id="aff8-0272989X11398489">Department of Medicine, University of Toronto (MK)</aff>
<aff id="aff9-0272989X11398489">Department of Mathematics and Statistics, University of Guelph, Guelph, Ontario, Canada (CTB)</aff>
<author-notes>
<corresp id="corresp1-0272989X11398489">Chris T. Bauch, Department of Mathematics and Statistics, University of Guelph, Room 536 MacNaughton Building, Guelph, Ontario, Canada N1G 2W1; telephone: (519) 824-4120 ext. 53079; fax: (519) 837-0221; e-mail: <email>cbauch@uoguelph.ca</email>.</corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>1</month>
<year>2012</year>
</pub-date>
<volume>32</volume>
<issue>1</issue>
<fpage>167</fpage>
<lpage>175</lpage>
<history>
<date date-type="received">
<day>23</day>
<month>5</month>
<year>2007</year>
</date>
<date date-type="accepted">
<day>11</day>
<month>12</month>
<year>2010</year>
</date>
</history>
<abstract>
<p><bold>Background</bold>. Evaluating the cost-effectiveness of vaccine programs with dynamic modeling requires accurate estimates of incidence over time. Because infectious diseases are often underreported, supplementary data and statistical analyses are required to estimate true incidence. This study estimates the true incidence of hepatitis A virus (HAV) infection in Canada using a catalytic model. <bold>Methods</bold>. A catalytic model was used to reconcile HAV seroprevalence data with the corresponding true cumulative risk of infection estimated from incidence data. <bold>Results</bold>. The average annual reported incidence was 6.2 cases per 100 000 from 1980 to 1989 and 7.7/100 000 from 1990 to 1999, indicating that Canada is a low-incidence country. The seroprevalence in Canadian-born individuals (n = 7 studies) was approximately 1%−8% in ages &lt;20, 1%−11% in ages 20–29, 7%−29% in ages 30–39, and higher in older age groups. Between 1980 and 1995, the catalytic model estimated an average annual incidence of 60/100 000 (95% confidence interval, 33–524); approximately 7.73 (4.21–67.33) times the average annual reported incidence of 7.78/100 000. For a typical birth cohort of 403 434 Canadians born in 1990, the model predicted 32 750 HAV cases by age 39, with a corresponding seroprevalence of approximately 8.12% by the year 2029. <bold>Implications</bold>. Reliable estimates of true incidence of infectious disease are required for cost-effectiveness analysis of infectious disease programs. Catalytic models enable the synthesis of dispersed data, quantification of data limitations, and reconciliation of these limitations to estimate true incidence for economic evaluations.</p>
</abstract>
<kwd-group>
<kwd>hepatitis A</kwd>
<kwd>prevalence</kwd>
<kwd>incidence</kwd>
<kwd>decision support techniques</kwd>
</kwd-group>
<custom-meta-wrap>
<custom-meta>
<meta-name>cover-date</meta-name>
<meta-value>January–February 2012</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<p>Hepatitis A virus (HAV) is prominent in many areas of the world.<sup><xref ref-type="bibr" rid="bibr1-0272989X11398489">1</xref>–<xref ref-type="bibr" rid="bibr3-0272989X11398489">3</xref></sup> In countries with low endemicity, adults are at risk for infection with HAV due to high-risk activities and disease importation.<sup><xref ref-type="bibr" rid="bibr4-0272989X11398489">4</xref></sup> Safe and effective HAV vaccines have been available since the mid-1990s.<sup><xref ref-type="bibr" rid="bibr5-0272989X11398489">5</xref>,<xref ref-type="bibr" rid="bibr6-0272989X11398489">6</xref></sup> In the United States, the hepatitis A childhood immunization strategy has evolved from vaccinating children living in communities with high and medium endemicity in 1996 and 1999 to routine vaccination of children nationwide in 2005.<sup><xref ref-type="bibr" rid="bibr7-0272989X11398489">7</xref>,<xref ref-type="bibr" rid="bibr8-0272989X11398489">8</xref></sup> Other low-endemicity countries continue with vaccine programs targeting high-risk groups,<sup><xref ref-type="bibr" rid="bibr9-0272989X11398489">9</xref></sup> although routine vaccination programs for children or adolescents are an alternative option.</p>
<p>The cost-effectiveness between targeted and routine vaccination programs is expected to be smaller than the cost-effectiveness between routine vaccinations versus no vaccination.<sup><xref ref-type="bibr" rid="bibr10-0272989X11398489">10</xref></sup> Analyses based upon dynamic models of HAV transmission could increase the sensitivity of detecting such small differences.<sup><xref ref-type="bibr" rid="bibr11-0272989X11398489">11</xref></sup> However, knowledge of the true incidence of HAV infection is required for such transmission models. We are interested in robust approaches to estimate true incidence to be used as input data for dynamic models of HAV transmission.</p>
<p>In most countries, the true incidence of HAV is unknown. Reported cases are an unreliable indicator of the true incidence because the infection is often not clinically apparent (subclinical) and symptomatic cases are not always reported (underreporting).<sup><xref ref-type="bibr" rid="bibr4-0272989X11398489">4</xref></sup> Measuring incidence directly with serial seroprevalence surveys is impractical because it is resource intensive.<sup><xref ref-type="bibr" rid="bibr4-0272989X11398489">4</xref></sup> Data from cross-sectional seroprevalence surveys, if available, cannot be used to directly infer time-specific incidence without some additional modeling steps.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup></p>
<p><italic>Catalytic</italic> models were first used to model age-specific changes in the force of infection, the rate at which individuals who have not been exposed to the virus (or susceptibles) acquire infection.<sup><xref ref-type="bibr" rid="bibr13-0272989X11398489">13</xref></sup> Integrating acute disease surveillance data with seroprevalence data from 2 national cross-sectional surveys, a catalytic model has been used to estimate the true incidence of HAV infection in the United States.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> According to results from the study, the estimate of true incidence in the United States was approximately 10 times the reported incidence and declined by 4.5% per year over the modeling duration.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> This information was subsequently used in other studies to quantify the impact of hepatitis A immunization in the United States in the late 1990s.<sup><xref ref-type="bibr" rid="bibr8-0272989X11398489">8</xref>,<xref ref-type="bibr" rid="bibr14-0272989X11398489">14</xref></sup></p>
<p>The catalytic model application in the United States was based upon seroprevalence data from 2 national cross-sectional surveys.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> However, it is less clear whether such a catalytic model can be used to generate reliable estimates of true incidence in countries where national seroprevalence surveys are not available and alternative seroprevalence data are limited in scope and comprehensiveness. We aimed to estimate the true incidence of HAV infection in Canada, a low-endemicity country with fragmented seroprevalence data.</p>
<sec id="section1-0272989X11398489" sec-type="methods">
<title>Methods</title>
<sec id="section2-0272989X11398489">
<title>Catalytic Model</title>
<p>Following the notation by Armstrong and Bell,<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> the force of infection—the percentage of susceptible individuals of age <italic>a</italic> infected in year <italic>t</italic>—is given by λ(<italic>a</italic>, <italic>t</italic>). We wish to know the resulting cumulative percentage infected in a cohort that is at age <italic>A</italic> in year <italic>T</italic>. The cumulative exposure <italic>F</italic>(<italic>A</italic>, <italic>T</italic>) experienced by this cohort in the <italic>A</italic> years since its birth is the force of infection experienced at age 1 in year <italic>T</italic> − <italic>A</italic>, plus the force of infection experienced at age 2 in year <italic>T</italic> − <italic>A</italic> + 1, . . ., plus the force of infection experienced at age <italic>a</italic> in year <italic>T</italic> − <italic>A</italic> + <italic>a</italic>, . . ., plus the force of infection experienced at age <italic>A</italic> in year <italic>T</italic>. This cumulative exposure experienced from birth (<italic>a</italic> = 0) to the present (<italic>a</italic> = <italic>A</italic>) by individuals in the birth cohort can be expressed as an integral</p>
<p><disp-formula id="disp-formula1-0272989X11398489">
<mml:math display="block" id="math1-0272989X11398489">
<mml:mi>F</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>A</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mstyle displaystyle="true">
<mml:mrow>
<mml:munderover>
<mml:mo stretchy="false">∫</mml:mo>
<mml:mn>0</mml:mn>
<mml:mi>A</mml:mi>
</mml:munderover>
<mml:mrow>
<mml:mi>λ</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>a</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:mstyle>
</mml:math>
<graphic alternate-form-of="disp-formula1-0272989X11398489" xlink:href="10.1177_0272989X11398489-eq1.tif"/>
</disp-formula>
</p>
<p>where <italic>t</italic> = <italic>T</italic> − <italic>A</italic> + <italic>a</italic> from the arguments above. Because the cumulative exposure in the cohort is <italic>F</italic>(<italic>A</italic>, <italic>T</italic>), the proportion of individuals in the cohort not infected by year <italic>T</italic> is given by exp(−<italic>F</italic>(<italic>A</italic>, <italic>T</italic>)); hence, the proportion of individuals in the cohort infected by year <italic>T</italic> is simply 1 minus that quantity, or</p>
<p><disp-formula id="disp-formula2-0272989X11398489">
<mml:math display="block" id="math2-0272989X11398489">
<mml:mi>P</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>A</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mo>−</mml:mo>
<mml:mi>F</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>A</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mrow>
<mml:mo>(</mml:mo>
<mml:mrow>
<mml:mo>−</mml:mo>
<mml:mstyle displaystyle="true">
<mml:mrow>
<mml:munderover>
<mml:mo stretchy="false">∫</mml:mo>
<mml:mn>0</mml:mn>
<mml:mi>A</mml:mi>
</mml:munderover>
<mml:mrow>
<mml:mi>λ</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>a</mml:mi>
</mml:mrow>
</mml:mrow>
</mml:mstyle>
</mml:mrow>
<mml:mo>)</mml:mo>
<mml:mo>.</mml:mo>
</mml:mrow>
</mml:math>
<graphic alternate-form-of="disp-formula2-0272989X11398489" xlink:href="10.1177_0272989X11398489-eq2.tif"/>
</disp-formula>
</p>
<p>To simplify estimation, one can moreover assume that age and time are independent in the force of infection; hence, it can be modeled as the product of 2 functions:</p>
<p><disp-formula id="disp-formula3-0272989X11398489">
<mml:math display="block" id="math3-0272989X11398489">
<mml:mi>λ</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>F</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>·</mml:mo>
<mml:mi>G</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">),</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula3-0272989X11398489" xlink:href="10.1177_0272989X11398489-eq3.tif"/>
</disp-formula>
</p>
<p>where <italic>F</italic>(<italic>a</italic>) is a function describing the age-specific force of infection (and is distinct from the exposure function <italic>F</italic>(<italic>A</italic>, <italic>T</italic>)), and <italic>G</italic>(<italic>t</italic>) is a function describing how the force of infection evolves over time.</p>
<p>Here, the cumulative percentage infected in a cohort of age <italic>A</italic> and time <italic>T</italic>, <italic>P</italic>(<italic>A</italic>, <italic>T</italic>), is taken to be identical to the seroprevalence in the Canadian-born cohort of age <italic>A</italic> at time <italic>T</italic>. Thus <italic>P</italic>(<italic>A</italic>, <italic>T</italic>) is hereafter referred to as seroprevalence. Similarly, the force of infection λ(<italic>a</italic>, <italic>t</italic>) can be expressed as some function of the incidence of new infections as reflected in case reports. Therefore, <xref ref-type="disp-formula" rid="disp-formula2-0272989X11398489">Equation 2</xref> makes it possible to integrate age-stratified reported incidence data with seroprevalence data in a birth cohort at a given time to estimate epidemiologically important parameters such as the force of infection λ(<italic>a</italic>, <italic>t</italic>), via model fitting.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref>,<xref ref-type="bibr" rid="bibr15-0272989X11398489">15</xref>,<xref ref-type="bibr" rid="bibr16-0272989X11398489">16</xref></sup></p>
<p>Key steps in fitting the model include 1) obtaining seroprevalence data; 2) obtaining reported incidence data; 3) adjusting reported incidence to reflect theage-specific and time-specific components of the force of infection λ(<italic>a</italic>, <italic>t</italic>) in <xref ref-type="disp-formula" rid="disp-formula3-0272989X11398489">Equation 3</xref>, <xref ref-type="disp-formula" rid="disp-formula4-0272989X11398489">4</xref>) fitting the catalytic model to derive parameter estimates and long-term predictions; and 5) conducting sensitivity analyses to address uncertainty in model inputs.<sup><xref ref-type="bibr" rid="bibr17-0272989X11398489">17</xref></sup></p>
</sec>
<sec id="section3-0272989X11398489">
<title>Step 1: Obtaining Seroprevalence Data</title>
<p>We obtained seroprevalence data from surveys of HAV antibodies in Canadian participants. The included surveys were identified through a systematic review.<sup><xref ref-type="bibr" rid="bibr18-0272989X11398489">18</xref></sup> <xref ref-type="fig" rid="fig1-0272989X11398489">Figure 1A</xref> displays the seroprevalence estimates in Canadian-born cohorts that most likely reflected local transmission patterns. We extracted these estimates to provide data for the response variable <italic>P</italic>(<italic>A</italic>, <italic>T</italic>) in <xref ref-type="disp-formula" rid="disp-formula2-0272989X11398489">Equation 2</xref>.</p>
<fig id="fig1-0272989X11398489" position="float">
<label>Figure 1</label>
<caption>
<p>Age-specific seroprevalence (%) abstracted from clinical studies identified through a systematic review.<sup><xref ref-type="bibr" rid="bibr18-0272989X11398489">18</xref></sup> The column “Author” displays the first author and year of publication of the included studies; “Population” the major age groups, participant characteristics, and year of data collection in the included studies; “Age” the age groups according to the original study reports; and “<italic>n</italic>” the sample size. Plotted lines are percent estimates of participants with positive HAV antibodies and their corresponding 95% confidence intervals. A total of 7 studies contributed 20 data points in <xref ref-type="fig" rid="fig1-0272989X11398489">Figure 1A</xref> and 10 studies contributed 30 data points in <xref ref-type="fig" rid="fig1-0272989X11398489">Figure 1B</xref>. NS, Nova Scotia; BC, British Columbia; G6, Grade 6 students; CF, Canadian Forces.</p>
</caption>
<graphic xlink:href="10.1177_0272989X11398489-fig1.tif"/>
</fig>
<p><xref ref-type="fig" rid="fig1-0272989X11398489">Figure 1B</xref> displays the seroprevalence estimates <italic>P</italic><sub>all</sub>(<italic>a</italic>) that reflected the total immunity level in the population, We extracted these estimates using data from all Canadians, including foreign-born individuals who might have been infected prior to immigration. We used them in Step 3 to estimate (1 − <italic>P</italic><sub>all</sub>(<italic>a</italic>)), the age-specific proportion of susceptible individuals in the population. The age-specific seroprevalence estimates <italic>P</italic><sub>all</sub>(<italic>a</italic>) were derived and, if necessary, pooled across survey studies using the Dersimonian-Laird random-effects meta-analytical approach,<sup><xref ref-type="bibr" rid="bibr19-0272989X11398489">19</xref></sup> for age groups &lt;10 (<italic>n</italic> = 1 study); 10–19 (<italic>n</italic> = 6 studies); 20–29 (<italic>n</italic> = 6 studies); 30–39 (<italic>n</italic> = 5 studies); 40–49 (<italic>n</italic> = 3 studies); and &gt;50 (<italic>n</italic> = 4 studies).<sup><xref ref-type="bibr" rid="bibr18-0272989X11398489">18</xref></sup> Across surveys, the reported estimates <italic>P<sub>all</sub></italic>(<italic>a</italic>) varied substantially with respect to studied populations, timing, and variation in the reported age groups.<sup><xref ref-type="bibr" rid="bibr18-0272989X11398489">18</xref></sup> The impact of this heterogeneity on modeled estimates and projections was assessed via sensitivity analyses (Step 5).</p>
</sec>
<sec id="section4-0272989X11398489">
<title>Step 2: Obtaining Reported Incidence Data</title>
<p>Data pertaining to the annual age-specific reported incidence <italic>I</italic>(<italic>a</italic>) from 1980 to 2003 were obtained from the National Notifiable Disease Registry of Canada.<sup><xref ref-type="bibr" rid="bibr20-0272989X11398489">20</xref></sup> According to the national surveillance program, the case definition is a laboratory confirmation of HAV infection (i.e., positive immunoglobulin M antibody to HAV) with or without symptoms. Hepatitis A incidence is known to vary cyclically, with peaks in outbreak activity every 6–8 years depending on place and time. This cyclicity is apparent in <xref ref-type="fig" rid="fig2-0272989X11398489">Figure 2</xref>, where one observes peaks in 1985 and 1991. Incidence appears to be climbing again after a trough in 1994, but it is clear by the year 2000 that this pattern has been interrupted. The vaccine was introduced in targeted groups and for outbreak control in the mid-1990s.<sup><xref ref-type="bibr" rid="bibr21-0272989X11398489">21</xref></sup> The main analysis was conducted using data from 1980 to 1995, where the reported incidence data were not under any influence of HAV vaccines.</p>
<fig id="fig2-0272989X11398489" position="float">
<label>Figure 2</label>
<caption>
<p>Age-adjusted reported cases (left-vertical axis) and reported incidence per 100 000 (right vertical axis) of hepatitis A in Canada from 1980 to 2003.</p>
</caption>
<graphic xlink:href="10.1177_0272989X11398489-fig2.tif"/>
</fig>
</sec>
<sec id="section5-0272989X11398489">
<title>Step 3: Adjusting Reported Incidence</title>
<p>First, the age-specific component of the force of infection <italic>F</italic>(<italic>a</italic>) in <xref ref-type="disp-formula" rid="disp-formula2-0272989X11398489">Equation 2</xref>, defined as the percent of susceptible individuals of age <italic>a</italic> infected per year, was estimated as follows:</p>
<p><disp-formula id="disp-formula4-0272989X11398489">
<mml:math display="block" id="math4-0272989X11398489">
<mml:mi>F</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mi>β</mml:mi>
<mml:mo>·</mml:mo>
<mml:msub>
<mml:mi>I</mml:mi>
<mml:mrow>
<mml:mtext>adj</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mfrac>
<mml:mrow>
<mml:mi>β</mml:mi>
<mml:mo>∗</mml:mo>
<mml:mi>I</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
<mml:mrow>
<mml:mo stretchy="false">(</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:msub>
<mml:mi>P</mml:mi>
<mml:mrow>
<mml:mi>a</mml:mi>
<mml:mi>l</mml:mi>
<mml:mi>l</mml:mi>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>∗</mml:mo>
<mml:mi>P</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>J</mml:mi>
<mml:mo>|</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mfrac>
</mml:math>
<graphic alternate-form-of="disp-formula4-0272989X11398489" xlink:href="10.1177_0272989X11398489-eq4.tif"/>
</disp-formula>
</p>
<p>where the annual <italic>reported</italic> incidence <italic>I</italic>(<italic>a</italic>) represents the percentage of individuals of age group <italic>a</italic> becoming infected per year. For each age group <italic>a</italic>, <italic>I</italic>(<italic>a</italic>) was averaged from 1980 to 1995 to remove any short-term cyclical effects.<sup><xref ref-type="bibr" rid="bibr22-0272989X11398489">22</xref></sup> Similar to the approach proposed by Armstrong and Bell,<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> we made 4 adjustments to the reported incidence <italic>I</italic>(<italic>a</italic>) to capture its contribution to the force of infection.</p>
<sec id="section6-0272989X11398489">
<title>Adjustment 1</title>
<p>The reported incidence <italic>I</italic>(<italic>a</italic>) was divided by <italic>P</italic>(<italic>J | a</italic>), the probability of developing jaundice during acute infection in age group <italic>a</italic>, to account for subclinical infections that were assumed not to have been recognized or reported, thus yielding the true percentage of infections in age group <italic>a</italic>.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> Here we assumed that HAV infections without symptoms of jaundice were less likely to trigger a laboratory confirmation according to the case definition described in Step 2. We extracted the estimated age-specific probabilities of jaundice <italic>P</italic>(<italic>J | a</italic>) from Armstrong and Bell.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> These estimates indicate high subclinical infections in children and adolescents, approximately 7.2% (95% confidence interval, 4.7%−10.9%) in ages 0–4, 37.1% (30.7%−43.8%) in ages 5–9, 70.7% (58.8%−79.4%) in ages 10–17, and 85.2% (79.9%−89.2%) in ages ≥18.</p>
</sec>
<sec id="section7-0272989X11398489">
<title>Adjustment 2</title>
<p>The true percentage of infections <italic>I</italic>(<italic>a</italic>) <italic>/ P</italic>(<italic>J|a</italic>) was then divided by the proportion susceptible (1 − <italic>P</italic><sub>all</sub>(<italic>a</italic>)) because the force of infection is defined as the percentage of infections in the part of the cohort that is susceptible. This quantity is hereafter referred to as the <italic>I</italic><sub>adj</sub>(<italic>a</italic>), the adjusted incidence in susceptibles;</p>
</sec>
<sec id="section8-0272989X11398489">
<title>Adjustment 3</title>
<p>Finally, <italic>I</italic><sub>adj</sub>(<italic>a</italic>) was further adjusted by an underreporting factor β (β ≥ 1), representing any other sources of underreporting. Note that this method also permits fitted values of β &lt; 1 for diseases that are overreported.</p>
</sec>
<sec id="section9-0272989X11398489">
<title>Adjustment 4</title>
<p>A common pattern that was observed in past decades in many advanced countries was declining infection risk attributable to improving sanitation and hygiene, which implies a declining force of infection.<sup><xref ref-type="bibr" rid="bibr4-0272989X11398489">4</xref></sup> Hence, in <xref ref-type="disp-formula" rid="disp-formula3-0272989X11398489">Equation 3</xref>, the time-specific component of the force of infection was assumed to decline exponentially from 1980 onward at an annual rate δ such that</p>
<p><disp-formula id="disp-formula5-0272989X11398489">
<mml:math display="block" id="math5-0272989X11398489">
<mml:mi>G</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>t</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:msub>
<mml:mi>G</mml:mi>
<mml:mn>0</mml:mn>
</mml:msub>
<mml:mo>·</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">[</mml:mo>
<mml:mo>−</mml:mo>
<mml:mi>δ</mml:mi>
<mml:mo>·</mml:mo>
<mml:mtext>t</mml:mtext>
<mml:mo stretchy="false">],</mml:mo>
</mml:math>
<graphic alternate-form-of="disp-formula5-0272989X11398489" xlink:href="10.1177_0272989X11398489-eq5.tif"/>
</disp-formula>
</p>
<p>where <italic>G</italic><sub>0</sub> is a constant.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> We note that this gradual decline typically occurs over a longer timescale than the 6- to 8-year timescale of the natural cycling of hepatitis A incidence, which is caused by a separate phenomenon. We also note that this long-term decline is evident in the S-shaped age-stratified seroprevalence profile in Canadian-born individuals in <xref ref-type="fig" rid="fig1-0272989X11398489">Figure 1A</xref>. In contrast to the low seroprevalence in recently born cohorts, the high seroprevalence in older cohorts reflect high risk exposure in previous decades. Models that assume a constant force of infection cannot reproduce the observed S-shaped in seroprevalence profiles.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref>,<xref ref-type="bibr" rid="bibr23-0272989X11398489">23</xref></sup></p>
</sec>
</sec>
<sec id="section10-0272989X11398489">
<title>Step 4: Fitting the Catalytic Model</title>
<p>Combining <xref ref-type="disp-formula" rid="disp-formula2-0272989X11398489">Equations 2</xref>–<xref ref-type="disp-formula" rid="disp-formula5-0272989X11398489">5</xref> yields</p>
<p><disp-formula id="disp-formula6-0272989X11398489">
<mml:math display="block" id="math6-0272989X11398489">
<mml:mi>P</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>A</mml:mi>
<mml:mo>,</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>=</mml:mo>
<mml:mn>1</mml:mn>
<mml:mo>−</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">(</mml:mo>
<mml:mstyle displaystyle="true">
<mml:mrow>
<mml:munderover>
<mml:mo stretchy="false">∫</mml:mo>
<mml:mn>0</mml:mn>
<mml:mi>A</mml:mi>
</mml:munderover>
<mml:mrow>
<mml:mi>β</mml:mi>
<mml:mo>·</mml:mo>
<mml:msub>
<mml:mi>I</mml:mi>
<mml:mrow>
<mml:mtext>adj</mml:mtext>
</mml:mrow>
</mml:msub>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo>·</mml:mo>
<mml:mi>exp</mml:mi>
<mml:mo stretchy="false">[</mml:mo>
<mml:mi>δ</mml:mi>
<mml:mo>·</mml:mo>
<mml:mo stretchy="false">(</mml:mo>
<mml:mi>M</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>T</mml:mi>
<mml:mo>+</mml:mo>
<mml:mi>A</mml:mi>
<mml:mo>−</mml:mo>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
<mml:mo stretchy="false">]</mml:mo>
<mml:mi>d</mml:mi>
<mml:mi>a</mml:mi>
<mml:mo stretchy="false">)</mml:mo>
</mml:mrow>
</mml:mrow>
<mml:mo>,</mml:mo>
</mml:mstyle>
</mml:math>
<graphic alternate-form-of="disp-formula6-0272989X11398489" xlink:href="10.1177_0272989X11398489-eq6.tif"/>
</disp-formula>
</p>
<p>where <italic>M</italic> denotes the mid-point of the years in which the reported incidence data were used and accounts for the constant <italic>G</italic><sub>0</sub> in <xref ref-type="disp-formula" rid="disp-formula5-0272989X11398489">Equation 5</xref>. The paired parameter (<inline-formula id="inline-formula1-0272989X11398489">
<mml:math display="inline" id="math7-0272989X11398489">
<mml:mover accent="true">
<mml:mi>β</mml:mi>
<mml:mo>⌢</mml:mo>
</mml:mover>
</mml:math>
</inline-formula>) was estimated by minimizing the difference between the prevalence <italic>P</italic>(<italic>A</italic>, <italic>T</italic>), which uses the seroprevalence data and the corresponding right side of the equation, which uses the reported incidence data in <xref ref-type="disp-formula" rid="disp-formula6-0272989X11398489">Equation 6</xref>.</p>
<p>A smoothing function was fitted to the relationship between <italic>I</italic><sub>adj</sub>(<italic>a</italic>) and age <italic>a</italic> to obtain a continuous approximation to the discrete age-structure in the reported incidence data (<xref ref-type="app" rid="app1-0272989X11398489">appendix</xref>). The catalytic model was fitted in 2 steps. First, δ was varied by increments of 0.01 from 0.00001 to 1.0.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> Given a fixed value of the parameter δ, the expression log(1 − <italic>P</italic>(<italic>A</italic>, <italic>T</italic>)) according to <xref ref-type="disp-formula" rid="disp-formula6-0272989X11398489">Equation 6</xref> becomes a linear function of the parameter β. A least-squares estimate of β was then derived from a univariate linear regression of log(1 − <italic>P</italic>(<italic>A</italic>, <italic>T</italic>)) = β · <italic>X</italic>.</p>
<p>Model goodness of fit was assessed using the fitted statistic <italic>R</italic><sup>2</sup> and residual plots.<sup><xref ref-type="bibr" rid="bibr24-0272989X11398489">24</xref></sup> Fitted values of the paired parameter (<inline-formula id="inline-formula2-0272989X11398489">
<mml:math display="inline" id="math8-0272989X11398489">
<mml:mover accent="true">
<mml:mi>δ</mml:mi>
<mml:mo>⌢</mml:mo>
</mml:mover>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula3-0272989X11398489">
<mml:math display="inline" id="math9-0272989X11398489">
<mml:mover accent="true">
<mml:mi>β</mml:mi>
<mml:mo>⌢</mml:mo>
</mml:mover>
</mml:math>
</inline-formula>) were selected to maximize the fitted statistic <italic>R</italic><sup>2</sup>. The 95% confidence intervals for estimates of (<inline-formula id="inline-formula4-0272989X11398489">
<mml:math display="inline" id="math10-0272989X11398489">
<mml:mover accent="true">
<mml:mi>δ</mml:mi>
<mml:mo>⌢</mml:mo>
</mml:mover>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula5-0272989X11398489">
<mml:math display="inline" id="math11-0272989X11398489">
<mml:mover accent="true">
<mml:mi>β</mml:mi>
<mml:mo>⌢</mml:mo>
</mml:mover>
</mml:math>
</inline-formula>) were derived by varying estimates of the age-specific subclinical infection probability <italic>P</italic>(<italic>J | a</italic>) from their lower to upper 95% confidence intervals.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> Age-specific estimates of the adjusted incidence <italic>I</italic><sub>adj</sub>(<italic>a</italic>) were derived according to <xref ref-type="disp-formula" rid="disp-formula4-0272989X11398489">Equation 4</xref> using the fitted values <inline-formula id="inline-formula6-0272989X11398489">
<mml:math display="inline" id="math12-0272989X11398489">
<mml:mover accent="true">
<mml:mi>β</mml:mi>
<mml:mo>⌢</mml:mo>
</mml:mover>
</mml:math>
</inline-formula>.</p>
<p>Estimates of the force of infection λ(<italic>a, t</italic>) for a hypothetical birth cohort of 1990 (<italic>n</italic> = 403 434) were derived via <xref ref-type="disp-formula" rid="disp-formula2-0272989X11398489">Equation 2</xref> using the fitted values (<inline-formula id="inline-formula7-0272989X11398489">
<mml:math display="inline" id="math13-0272989X11398489">
<mml:mover accent="true">
<mml:mi>δ</mml:mi>
<mml:mo>⌢</mml:mo>
</mml:mover>
</mml:math>
</inline-formula>, <inline-formula id="inline-formula8-0272989X11398489">
<mml:math display="inline" id="math14-0272989X11398489">
<mml:mover accent="true">
<mml:mi>β</mml:mi>
<mml:mo>⌢</mml:mo>
</mml:mover>
</mml:math>
</inline-formula>). Corresponding estimates of jaundiced or symptomatic infection incidence were calculated by applying the age-specific probability of jaundice <italic>P</italic>(<italic>J | a</italic>) to estimates of the true incidence <italic>F</italic>(<italic>a</italic>).</p>
</sec>
<sec id="section11-0272989X11398489">
<title>Step 5: Sensitivity Analysis</title>
<p>In the main analysis, 1980–1995 reported incidence data and seroprevalence data from studies with data collection in 1995 or before were used. Incidence data from 1995 to 2003 were in part influenced by targeted HAV vaccine programs, as the vaccines were first used around 1995 in Canada.<sup><xref ref-type="bibr" rid="bibr4-0272989X11398489">4</xref>,<xref ref-type="bibr" rid="bibr21-0272989X11398489">21</xref></sup> Including this late time period, however, allowed the inclusion of seroprevalence data from recent studies (<xref ref-type="fig" rid="fig2-0272989X11398489">Figure 2</xref>). In a sensitivity analysis, data from 1980 to 2003 were used.</p>
<p>Age-specific estimates of HAV seroprevalence among all Canadians varied substantially (<xref ref-type="fig" rid="fig2-0272989X11398489">Figure 2</xref>). In the main analysis, the pooled estimates from random-effects models for <italic>P</italic><sub>all</sub>(<italic>a</italic>) were used. Sensitivity analyses were also conducted by using the lower and upper bounds of the 95% confidence intervals of the pooled estimates.</p>
</sec>
</sec>
<sec id="section12-0272989X11398489" sec-type="results">
<title>Results</title>
<p>The systematic search yielded 7 studies<sup><xref ref-type="bibr" rid="bibr25-0272989X11398489">25</xref>–<xref ref-type="bibr" rid="bibr31-0272989X11398489">31</xref></sup> reporting 20 point estimates for seroprevalence among Canadian-born participants (<xref ref-type="fig" rid="fig1-0272989X11398489">Figure 1A</xref>).<sup><xref ref-type="bibr" rid="bibr18-0272989X11398489">18</xref></sup> Seroprevalence samples collected from these studies occurred between 1980 and 2003 (<xref ref-type="fig" rid="fig1-0272989X11398489">Figure 1</xref>). The seroprevalence in Canadian-born individuals was approximately 1%−8% in ages &lt;20 years, 1%−11% in ages 20–29 years, 7%−29% in ages 30–39 years, 50% in ages 40–49 years, and 60%−82% in ages ≥50 years (<xref ref-type="fig" rid="fig1-0272989X11398489">Figure 1A</xref>). A similar pattern was observed for all Canadians including foreign-born individuals, with large variation in each age group (<xref ref-type="fig" rid="fig1-0272989X11398489">Figure 1B</xref>). Point estimates in the age groups &gt;40 years were high and most likely influenced by the cohort effect, meaning that the high seroprevalence reflected lifelong immunity from HAV infection experienced by birth cohorts in past decades (<xref ref-type="fig" rid="fig1-0272989X11398489">Figure 1A</xref>).</p>
<p>In Canada, the average annual reported incidence was 6.2 cases per 100 000 (range 4.3–9.5) from 1980 to 1989 and 7.7 (5.9–0.8) from 1990 to 1999 (<xref ref-type="fig" rid="fig2-0272989X11398489">Figure 2</xref>). Coinciding with the use of HAV vaccines in targeted groups and outbreak control, there appeared to be a decreasing trend from 1995 to 2003, reaching below 2 cases per 100 000 from 2000 to 2003.</p>
<p>Modeled estimates of seroprevalence fitted the observed seroprevalence reported in survey studies for ages &lt;40 years (<xref ref-type="fig" rid="fig3-0272989X11398489">Figure 3</xref>). Limited seroprevalence data were available for modeled estimates in ages ≥40 years (<italic>n</italic> = 3 data points, <xref ref-type="fig" rid="fig3-0272989X11398489">Figure 3</xref>). The annual rate of decline in the force of infection over time was estimated to be δ = 0.12 (95% confidence interval, 0.08–0.15; <xref ref-type="table" rid="table1-0272989X11398489">Table 1</xref>). The underreporting factor estimated from the linear regression involving the response log(1 − <italic>P</italic>(<italic>A, T</italic>)) derived from <xref ref-type="disp-formula" rid="disp-formula6-0272989X11398489">Equation 6</xref> was β = 7.73 (4.21–67.33), with a goodness-of-fit statistic <italic>R</italic><sup>2</sup> = 0.86. This underreporting estimate suggests that for every reported HAV case, approximately 8 cases were not reported. In the sensitivity analysis, estimates of the annual declining rate δ and underreporting factor β exhibited large confidence intervals. The maximum boundaries across different confidence intervals for δ ranged from 0.05 to 0.15 and for β from 4.21 to 76.83 (<xref ref-type="table" rid="table1-0272989X11398489">Table 1</xref>).</p>
<fig id="fig3-0272989X11398489" position="float">
<label>Figure 3</label>
<caption>
<p>Observed age-specific seroprevalence data reported in 7 clinical studies are plotted as black dots. The solid line represents predicted seroprevalence at midstudy period estimated from the fitted catalytic model, with broken lines representing the 95% confidence interval derived from the fitted catalytic model.</p>
</caption>
<graphic xlink:href="10.1177_0272989X11398489-fig3.tif"/>
</fig>
<table-wrap id="table1-0272989X11398489" position="float">
<label>Table 1</label>
<caption>
<p>Parameter Estimates From the Main Analysis and Corresponding Sensitivity Analyses</p>
</caption>
<graphic alternate-form-of="table1-0272989X11398489" xlink:href="10.1177_0272989X11398489-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Declining Trend Parameter, δ (95% CI)</th>
<th align="center">Underreporting Factor, β (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Main analysis<sup><xref ref-type="table-fn" rid="table-fn2-0272989X11398489">a</xref></sup></td>
<td>0.12 (0.08–0.15)</td>
<td>7.73 (4.21–67.33)</td>
</tr>
<tr>
<td colspan="3">Varied incidence data</td>
</tr>
<tr>
<td> Sensitivity analysis with 1980–2003 data</td>
<td>0.10 (0.07–0.15)</td>
<td>9.83 (6.39–63.65)</td>
</tr>
<tr>
<td colspan="3">Varied HAV prevalence in all Canadians</td>
</tr>
<tr>
<td> Sensitivity analysis with lower bound<sup><xref ref-type="table-fn" rid="table-fn3-0272989X11398489">b</xref></sup></td>
<td>0.09 (0.07–0.13)</td>
<td>16.56 (6.89–76.83)</td>
</tr>
<tr>
<td> Sensitivity analysis with upper bound<sup><xref ref-type="table-fn" rid="table-fn4-0272989X11398489">c</xref></sup></td>
<td>0.13 (0.05–0.14)</td>
<td>3.88 (2.69–48.23)</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0272989X11398489">
<p>Note: CI, confidence interval; HAV, hepatitis A virus.</p>
</fn>
<fn id="table-fn2-0272989X11398489">
<label>a.</label>
<p>The main analysis was based upon incidence data from 1980–1995 and pooled estimates from random-effects model of HAV prevalence in all Canadians (data from <xref ref-type="fig" rid="fig2-0272989X11398489">Figure 2</xref>). The pooled estimates were used to adjust reported incidence data for the proportion susceptibles (i.e., in <xref ref-type="disp-formula" rid="disp-formula4-0272989X11398489">Equation 4</xref>).</p>
</fn>
<fn id="table-fn3-0272989X11398489">
<label>b.</label>
<p>Lower bounds from 95% confidence intervals of the pooled estimates from note <italic>a</italic>.</p>
</fn>
<fn id="table-fn4-0272989X11398489">
<label>c.</label>
<p>Upper bounds from 95% confidence intervals of the pooled estimates from note <italic>a</italic>.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<p>The reported incidence was adjusted to better reflect estimates of the force of infection (<xref ref-type="fig" rid="fig4-0272989X11398489">Figure 4</xref>). In ages 0 to 9 years, reported incidence substantially underestimated the true incidence, most possibly because of subclinical infection. For age groups ≥30 years, reported incidence also underestimated true incidence. Note that the seroprevalence estimates among all Canadians increased with age, leading to a decrease in the relative size of susceptibles in the older age groups and an increase in the gap between reported and adjusted incidence according to <xref ref-type="disp-formula" rid="disp-formula4-0272989X11398489">Equation 4</xref>.</p>
<fig id="fig4-0272989X11398489" position="float">
<label>Figure 4</label>
<caption>
<p>Reported and adjusted average annual incidence of hepatitis A in Canada, 1980–1995. Reported incidence data were available for each decade of age except for the age groups 40–59 and 60+. For each age group, the first bar shows the unadjusted reported incidence. The second bar shows incidence after adjustment for subclinical infection using the age-specific probability of jaundice <italic>P(J | a)</italic>. The third bar shows incidence after further adjusting the population denominator for the relative size of susceptibles <italic>[I(a)/(1 − P<sub>all</sub>(a))]</italic>. Additional adjustment for underreporting was possible according to <xref ref-type="disp-formula" rid="disp-formula4-0272989X11398489">Equation 4</xref> (data not shown in the graph).</p>
</caption>
<graphic xlink:href="10.1177_0272989X11398489-fig4.tif"/>
</fig>
<p>The model estimated an average annual incidence of 60.14 HAV cases per 100 000 in Canada (95% confidence interval, 32.75–523.83), approximately 7.73 times the average annual reported incidence of 7.78 cases per 100 000 from 1980 to 1995. For a typical birth cohort of 403 434 Canadians born in 1990, the model predicted 32 750 HAV cases by age 39, with a corresponding seroprevalence of approximately 8.12% by the year 2029 (<xref ref-type="table" rid="table2-0272989X11398489">Table 2</xref>). The cumulative number of cases in older age groups was predicted taking both the cohort effect and susceptibility into account (<xref ref-type="table" rid="table2-0272989X11398489">Table 2</xref>).</p>
<table-wrap id="table2-0272989X11398489" position="float">
<label>Table 2</label>
<caption>
<p>Long-Term Projection From the Catalytic Model for True Incidence of Hepatitis A Virus (HAV) Infection in a Canadian Birth Cohort of 1990 (<italic>n</italic> = 403 434)</p>
</caption>
<graphic alternate-form-of="table2-0272989X11398489" xlink:href="10.1177_0272989X11398489-table2.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Age Group</th>
<th align="center">Year</th>
<th align="center">HAV Cases<sup><xref ref-type="table-fn" rid="table-fn5-0272989X11398489">a</xref></sup></th>
<th align="center">Icteric Cases<sup><xref ref-type="table-fn" rid="table-fn5-0272989X11398489">a</xref></sup></th>
<th align="center">HAV Cases / 100 000</th>
<th align="center">Icteric Cases / 100 000</th>
<th align="center">Estimated Seroprevalence, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>0–9</td>
<td>1990-1999</td>
<td>7261</td>
<td>362</td>
<td>1800</td>
<td>90</td>
<td>1.80</td>
</tr>
<tr>
<td>10–19</td>
<td>2000-2009</td>
<td>3954</td>
<td>492</td>
<td>980</td>
<td>122</td>
<td>2.78</td>
</tr>
<tr>
<td>20–29</td>
<td>2010-2019</td>
<td>12 346</td>
<td>599</td>
<td>3060</td>
<td>148</td>
<td>5.84</td>
</tr>
<tr>
<td>30–39</td>
<td>2020-2029</td>
<td>9198</td>
<td>238</td>
<td>2280</td>
<td>59</td>
<td>8.12</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn5-0272989X11398489">
<label>a.</label>
<p>Cumulative number of cases in each age group (e.g., 7261 cases from birth to age 9 in the first age group).</p>
</fn>
</table-wrap-foot>
</table-wrap>
</sec>
<sec id="section13-0272989X11398489" sec-type="discussion">
<title>Discussion</title>
<p>This article provides an example of how catalytic modeling can be used to bridge the gap between reported incidence and seroprevalence data to estimate the true incidence pattern over time in a population. This information can be used to understand transmission dynamics of infectious diseases over time by distinguishing age and cohort effects on the force of infection. This type of modeling is particularly salient for epidemiologists and economic modelers attempting to estimate the future effects of infectious disease control programs, particularly vaccines, on a population’s health.</p>
<p>Cost-effectiveness analyses of disease control programs often rely on cohort models, which essentially consider the individual in isolation from the population and do not take population-level mechanisms of disease transmission into account.<sup><xref ref-type="bibr" rid="bibr10-0272989X11398489">10</xref></sup> They implicitly assume that the force of infection does not change when control programs are implemented, which is rarely the case. Hence, they can either underestimate or overestimate cost-effectiveness of the intervention.<sup><xref ref-type="bibr" rid="bibr11-0272989X11398489">11</xref></sup> In contrast, dynamic models take into account mechanisms that govern the time evolution of epidemiological measures, such as the number of infected individuals, mortality rates, and force of infection. In principle, they are more accurate than corresponding cohort models for cost-effectiveness analysis of control programs.<sup><xref ref-type="bibr" rid="bibr11-0272989X11398489">11</xref>,33</sup> However, application of dynamic models requires knowledge of the true incidence of infection; hence, catalytic modeling or a similar approach is necessary.</p>
<p>The catalytic model equations are a function of time and age. In principle, they can be used to predict future incidence or seroprevalence in any age class. However, catalytic models are always fitted to data from a specified time period; therefore, they are not appropriate for predicting incidence or seroprevalence outside of that window if there has been a perturbation that could influence incidence, such as a change in demographic trends or the introduction of a vaccination program. To predict seroprevalence or incidence for a time period outside the window used to fit the catalytic model (such as for future predictions where there is not yet data), a dynamic model is needed. Dynamic models incorporate the mechanisms of disease transmission and can therefore be used to predict what changes should occur under new circumstances, based on what is presently known.<sup><xref ref-type="bibr" rid="bibr10-0272989X11398489">10</xref>,<xref ref-type="bibr" rid="bibr23-0272989X11398489">23</xref>,<xref ref-type="bibr" rid="bibr32-0272989X11398489">32</xref></sup></p>
<p>In addition to offering an example of the use of catalytic modeling with fragmented and limited data, our results also highlight the potential biases associated with the use of readily available epidemiological data in cost-effectiveness evaluation of infectious disease control programs. Data from notifiable disease reporting substantially underestimate true incidence because of subclinical symptoms in HAV infection<sup><xref ref-type="bibr" rid="bibr4-0272989X11398489">4</xref></sup> and underreporting of clinical cases.<sup><xref ref-type="bibr" rid="bibr12-0272989X11398489">12</xref></sup> Prevalence data from cross-sectional surveys were fragmented and suffered from a cohort effect; the high prevalence in the older age groups most likely reflected infection risk of past decades.<sup><xref ref-type="bibr" rid="bibr23-0272989X11398489">23</xref>,<xref ref-type="bibr" rid="bibr32-0272989X11398489">32</xref></sup> Reported prevalence from surveys including foreign-born subjects might not exclusively reflect local transmissibility. The uncertainty induced by these potential sources of bias in the input data should be recognized, quantified, and assessed in cost-effectiveness analyses of infectious disease control programs.</p>
<p>A number of key assumptions were made in the catalytic model we used. First, we assumed that HAV infection leads to lifelong immunity. The age-dependent force of infection was assumed to be constant and the susceptible population homogeneous with respect to infection exposure. A population with stable age distribution was assumed, as it was convenient to ignore deaths and migration to and from the population.<sup><xref ref-type="bibr" rid="bibr22-0272989X11398489">22</xref></sup> With respect to input data to the model, seroprevalence estimates from small studies and heterogeneous study populations were generalized to represent Canadian estimates.</p>
<p>In summary, catalytic models integrate reported incidence and seroprevalence data, providing reasonably reliable estimates of past, current, and projected force of infection. They provide a logical structure to link highly dispersed data, quantify limitations in the data sources, and reconcile these limitations to derive estimates of true incidence. They are useful to epidemiologic and economic modelers attempting to estimate the cost-effectiveness of disease control programs through dynamic modeling.</p>
</sec>
</body>
<back>
<app-group>
<app id="app1-0272989X11398489">
<title>Appendix</title>
<p>A 2-parameter exponential function form was used for the relationship between <italic>I</italic><sub>adj</sub>(<italic>a</italic>) and age <italic>a</italic>, <italic>I</italic><sub>adj</sub>(<italic>a</italic>) = exp(−α · <italic>a</italic><sup>τ</sup>). Fitted values for (α, τ) were obtained through fitting the univariate linear regression log(−log(<italic>I</italic><sub>adj</sub>(<italic>a</italic>)) = α + τ · log(<italic>a</italic>). This resulted in α = 5.40 (95% confidence interval, 5.10–5.87), τ = 0.15 (0.13–0.18), and a goodness-of-fit <italic>R</italic><sup>2</sup> of 0.92.</p>
</app>
</app-group>
<ack>
<p>We express our gratitude for the guidance we received from Dr. Bernard Duval (deceased). We thank Drs. Arni Rao and Vladimir Gilca for their guidance during the conduct of this study, as well as Richard Foty and Yang Liu for their assistance with the data collection and analysis.</p>
</ack>
<fn-group>
<fn fn-type="presented-at">
<p>This study was orally presented at the 26th Annual Meeting of the Society for Medical Decision Making in Philadelphia in October 2004 and at the 21st International Conference on Pharmacoepidemiology &amp; Therapeutic Risk Management in Tennessee in August 2005.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>Financial support for this study was provided by a combined grant from the Canadian Institutes of Health Research (CIHR) and GlaxoSmithKline, Canada. The funding agreement ensured the authors’ independence in designing the study, interpreting the data, writing, and publishing the report. Dr. Murray Krahn is sponsored, in part, by an Investigator Award from CIHR and the F. Norman Hughes Chair in Pharmacoeconomics, Faculty of Pharmacy, University of Toronto. During the study, Andrea C. Tricco was funded by a University of Ottawa Excellence Award, a CIHR Frederick Banting and Charles Best Canada Graduate Scholarship, and the CIHR Institute of Health Services and Policy Research Rising Star Award.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0272989X11398489">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cuthbert</surname><given-names>JA</given-names></name>
</person-group>. <article-title>Hepatitis A: old and new</article-title>. <source>Clin Microbiol Rev</source>. <year>2001</year>;<volume>14</volume>(<issue>1</issue>):<fpage>38</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr2-0272989X11398489">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gust</surname><given-names>ID</given-names></name>
</person-group>. <article-title>Epidemiological patterns of hepatitis A in different parts of the world</article-title>. <source>Vaccine</source>. <year>1992</year>;<volume>10</volume>(<issue>Suppl 1</issue>):<fpage>S56</fpage>–<lpage>S58</lpage>.</citation>
</ref>
<ref id="bibr3-0272989X11398489">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tapia-Conyer</surname><given-names>R</given-names></name>
<name><surname>Santos</surname><given-names>JI</given-names></name>
<name><surname>Cavalcanti</surname><given-names>AM</given-names></name>
<name><surname>Urdaneta</surname><given-names>E</given-names></name>
<name><surname>Rivera</surname><given-names>L</given-names></name>
<name><surname>Manterola</surname><given-names>A</given-names></name>
<etal/>
</person-group>. <article-title>Hepatitis A in Latin America: a changing epidemiologic pattern</article-title>. <source>Am J Trop Med Hyg</source>. <year>1999</year>;<volume>61</volume>(<issue>5</issue>):<fpage>825</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr4-0272989X11398489">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scheifele</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Hepatitis A vaccines: the growing case for universal immunisation of children</article-title>. <source>Expert Opin Pharmacother</source>. <year>2005</year>;<volume>6</volume>(<issue>2</issue>):<fpage>157</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr5-0272989X11398489">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Scheifele</surname><given-names>DW</given-names></name>
<name><surname>Ochnio</surname><given-names>J</given-names></name>
</person-group>. <article-title>Hepatitis A vaccine: is it being used to best advantage?</article-title> <source>CMAJ</source>. <year>2002</year>;<volume>167</volume>(<issue>1</issue>):<fpage>44</fpage>–<lpage>5</lpage>.</citation>
</ref>
<ref id="bibr6-0272989X11398489">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Furesz</surname><given-names>J</given-names></name>
<name><surname>Scheifele</surname><given-names>DW</given-names></name>
<name><surname>Palkonyay</surname><given-names>L</given-names></name>
</person-group>. <article-title>Safety and effectiveness of the new inactivated hepatitis A virus vaccine</article-title>. <source>CMAJ</source>. <year>1995</year> <month>1</month>;<volume>152</volume>(<issue>3</issue>):<fpage>343</fpage>–<lpage>8</lpage>.</citation>
</ref>
<ref id="bibr7-0272989X11398489">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fiore</surname><given-names>AE</given-names></name>
<name><surname>Wasley</surname><given-names>A</given-names></name>
<name><surname>Bell</surname><given-names>BP</given-names></name>
</person-group>. <article-title>Prevention of hepatitis A through active or passive immunization: recommendations of the Advisory Committee on Immunization Practices (ACIP)</article-title>. <source>MMWR Recomm Rep</source>. <year>2006;</year>
<volume>55</volume>(<issue>RR-7</issue>):<fpage>1</fpage>–<lpage>23</lpage>.</citation>
</ref>
<ref id="bibr8-0272989X11398489">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Samandari</surname><given-names>T</given-names></name>
<name><surname>Bell</surname><given-names>BP</given-names></name>
<name><surname>Armstrong</surname><given-names>GL</given-names></name>
</person-group>. <article-title>Quantifying the impact of hepatitis A immunization in the United States, 1995–2001</article-title>. <source>Vaccine</source>. <year>2004</year>;<volume>22</volume>(<issue>31–32</issue>):<fpage>4342</fpage>–<lpage>50</lpage>.</citation>
</ref>
<ref id="bibr9-0272989X11398489">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stene-Johansen</surname><given-names>K</given-names></name>
<name><surname>Tjon</surname><given-names>G</given-names></name>
<name><surname>Schreier</surname><given-names>E</given-names></name>
<name><surname>Bremer</surname><given-names>V</given-names></name>
<name><surname>Bruisten</surname><given-names>S</given-names></name>
<name><surname>Ngui</surname><given-names>SL</given-names></name>
<etal/>
</person-group>. <article-title>Molecular epidemiological studies show that hepatitis A virus is endemic among active homosexual men in Europe</article-title>. <source>J Med Virol</source>. <year>2007</year>;<volume>79</volume>(<issue>4</issue>):<fpage>356</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr10-0272989X11398489">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bauch</surname><given-names>CT</given-names></name>
<name><surname>Rao</surname><given-names>AS</given-names></name>
<name><surname>Pham</surname><given-names>BZ</given-names></name>
<name><surname>Krahn</surname><given-names>M</given-names></name>
<name><surname>Gilca</surname><given-names>V</given-names></name>
<name><surname>Duval</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>A dynamic model for assessing universal Hepatitis A vaccination in Canada</article-title>. <source>Vaccine</source>. <year>2007</year>;<volume>25</volume>(<issue>10</issue>):<fpage>1719</fpage>–<lpage>26</lpage>.</citation>
</ref>
<ref id="bibr11-0272989X11398489">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Edmunds</surname><given-names>WJ</given-names></name>
<name><surname>Medley</surname><given-names>GF</given-names></name>
<name><surname>Nokes</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Evaluating the cost-effectiveness of vaccination programmes: a dynamic perspective</article-title>. <source>Stat Med</source>. <year>1999</year>;<volume>18</volume>(<issue>23</issue>):<fpage>3263</fpage>–<lpage>82</lpage>.</citation>
</ref>
<ref id="bibr12-0272989X11398489">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Armstrong</surname><given-names>GL</given-names></name>
<name><surname>Bell</surname><given-names>BP</given-names></name>
</person-group>. <article-title>Hepatitis A virus infections in the United States: model-based estimates and implications for childhood immunization</article-title>. <source>Pediatrics</source>. <year>2002</year>;<volume>109</volume>(<issue>5</issue>):<fpage>839</fpage>–<lpage>45</lpage>.</citation>
</ref>
<ref id="bibr13-0272989X11398489">
<label>13.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Muench</surname><given-names>H</given-names></name>
</person-group>. <article-title>Catalytic Models in Epidemiology</article-title>. <publisher-loc>Cambridge, MA</publisher-loc>: <publisher-name>Harvard University Press</publisher-name>; <year>1959</year>.</citation>
</ref>
<ref id="bibr14-0272989X11398489">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Effelterre</surname><given-names>TP</given-names></name>
<name><surname>Zink</surname><given-names>TK</given-names></name>
<name><surname>Hoet</surname><given-names>BJ</given-names></name>
<name><surname>Hausdorff</surname><given-names>WP</given-names></name>
<name><surname>Rosenthal</surname><given-names>P</given-names></name>
</person-group>. <article-title>A mathematical model of hepatitis a transmission in the United States indicates value of universal childhood immunization</article-title>. <source>Clin Infect Dis</source>. <year>2006</year>;<volume>43</volume>(<issue>2</issue>):<fpage>158</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr15-0272989X11398489">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ades</surname><given-names>AE</given-names></name>
<name><surname>Nokes</surname><given-names>DJ</given-names></name>
</person-group>. <article-title>Modeling age- and time-specific incidence from seroprevalence: toxoplasmosis</article-title>. <source>Am J Epidemiol</source>. <year>1993</year>;<volume>137</volume>(<issue>9</issue>):<fpage>1022</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr16-0272989X11398489">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Grenfell</surname><given-names>BT</given-names></name>
<name><surname>Anderson</surname><given-names>RM</given-names></name>
</person-group>. <article-title>The estimation of age-related rates of infection from case notifications and serological data</article-title>. <source>J Hyg (Lond)</source>. <year>1985</year>;<volume>95</volume>(<issue>2</issue>):<fpage>419</fpage>–<lpage>36</lpage>.</citation>
</ref>
<ref id="bibr17-0272989X11398489">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Philips</surname><given-names>Z</given-names></name>
<name><surname>Bojke</surname><given-names>L</given-names></name>
<name><surname>Sculpher</surname><given-names>M</given-names></name>
<name><surname>Claxton</surname><given-names>K</given-names></name>
<name><surname>Golder</surname><given-names>S</given-names></name>
</person-group>. <article-title>Good practice guidelines for decision-analytic modelling in health technology assessment: a review and consolidation of quality assessment</article-title>. <source>Pharmacoeconomics</source>. <year>2006</year>;<volume>24</volume>(<issue>4</issue>):<fpage>355</fpage>–<lpage>71</lpage>.</citation>
</ref>
<ref id="bibr18-0272989X11398489">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pham</surname><given-names>B</given-names></name>
<name><surname>Duval</surname><given-names>B</given-names></name>
<name><surname>De</surname><given-names>SG</given-names></name>
<name><surname>Gilca</surname><given-names>V</given-names></name>
<name><surname>Tricco</surname><given-names>AC</given-names></name>
<name><surname>Ochnio</surname><given-names>J</given-names></name>
<etal/>
</person-group>. <article-title>Seroprevalence of hepatitis A infection in a low endemicity country: a systematic review</article-title>. <source>BMC Infect Dis</source>. <year>2005</year>;<volume>5</volume>:<fpage>56</fpage>.</citation>
</ref>
<ref id="bibr19-0272989X11398489">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>DerSimonian</surname><given-names>R</given-names></name>
<name><surname>Laird</surname><given-names>N</given-names></name>
</person-group>. <article-title>Meta-analysis in clinical trials</article-title>. <source>Control Clin Trials</source>. <year>1986</year>;<volume>7</volume>(<issue>3</issue>):<fpage>177</fpage>–<lpage>88</lpage>.</citation>
</ref>
<ref id="bibr20-0272989X11398489">
<label>20.</label>
<citation citation-type="web">
<collab>Public Health Agency of Canada. Notifiable Diseases Online</collab>.<comment>Available from: URL: <ext-link ext-link-type="uri" xlink:href="http://dsol-smedphac-aspcgcca/dsol-smed/ndis/index_ehtml">http://dsol-smedphac-aspcgcca/dsol-smed/ndis/index_ehtml</ext-link>
</comment>.</citation>
</ref>
<ref id="bibr21-0272989X11398489">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wu</surname><given-names>J</given-names></name>
<name><surname>Zou</surname><given-names>S</given-names></name>
<name><surname>Giulivi</surname><given-names>A</given-names></name>
</person-group>. <article-title>Current hepatitis A status in Canada</article-title>. <source>Can J Infect Dis Med Microbiol</source>. <year>2001</year>;<volume>12</volume>(<issue>6</issue>):<fpage>341</fpage>–<lpage>4</lpage>.</citation>
</ref>
<ref id="bibr22-0272989X11398489">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Griffiths</surname><given-names>DA</given-names></name>
</person-group>. <article-title>A catalytic model of infection for measles</article-title>. <source>Appl Stat</source>. <year>1974</year>;<volume>23</volume>:<fpage>330</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr23-0272989X11398489">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Srinivasa Rao</surname><given-names>AS</given-names></name>
<name><surname>Chen</surname><given-names>MH</given-names></name>
<name><surname>Pham</surname><given-names>BZ</given-names></name>
<name><surname>Tricco</surname><given-names>AC</given-names></name>
<name><surname>Gilca</surname><given-names>V</given-names></name>
<name><surname>Duval</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>Cohort effects in dynamic models and their impact on vaccination programmes: an example from hepatitis A</article-title>. <source>BMC Infect Dis</source>. <year>2006</year>;<volume>6</volume>:<fpage>174</fpage>.</citation>
</ref>
<ref id="bibr24-0272989X11398489">
<label>24.</label>
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>R</given-names></name>
</person-group>. <article-title>Plane Questions to Complex Questions: The Theory of Linear Models</article-title>. <publisher-loc>New York, NY</publisher-loc>: <publisher-name>Springer-Verlag</publisher-name>; <year>1987</year>.</citation>
</ref>
<ref id="bibr25-0272989X11398489">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Crewe</surname><given-names>MD</given-names></name>
<name><surname>Embil</surname><given-names>JA</given-names></name>
<name><surname>Garner</surname><given-names>JB</given-names></name>
</person-group>. <article-title>Prevalence of antibodies to hepatitis A virus in Nova Scotia children</article-title>. <source>Can Med Assoc J</source>. <year>1983</year>;<volume>128</volume>(<issue>10</issue>):<fpage>1195</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr26-0272989X11398489">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Payment</surname><given-names>P</given-names></name>
</person-group>. <article-title>Antibody levels to selected enteric viruses in a French-Canadian population in the province of Quebec</article-title>. <source>Immunol Infect Dis</source>. <year>1991</year>;<volume>1</volume>:<fpage>317</fpage>–<lpage>22</lpage>.</citation>
</ref>
<ref id="bibr27-0272989X11398489">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Duval</surname><given-names>B</given-names></name>
<name><surname>De Serres</surname><given-names>G</given-names></name>
<name><surname>Gilca</surname><given-names>V</given-names></name>
<name><surname>Ochnio</surname><given-names>J</given-names></name>
<name><surname>Scheifele</surname><given-names>DW</given-names></name>
</person-group>. <article-title>Nationwide Canadian study of hepatitis A antibody prevalence among children eight to thirteen years old</article-title>. <source>Pediatr Infect Dis J</source>. <year>2005</year>;<volume>24</volume>(<issue>6</issue>):<fpage>514</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr28-0272989X11398489">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Levy</surname><given-names>I</given-names></name>
<name><surname>Chen</surname><given-names>D</given-names></name>
<name><surname>Sherman</surname><given-names>M</given-names></name>
<name><surname>Smith</surname><given-names>D</given-names></name>
<name><surname>Krajden</surname><given-names>M</given-names></name>
</person-group>. <article-title>Hepatitis A virus seroprevalence in 1,000 university students in Toronto</article-title>. <source>Can Commun Dis Rep</source>. <year>2001</year> <month>1</month>;<volume>27</volume>(<issue>11</issue>):<fpage>93</fpage>–<lpage>6</lpage>.</citation>
</ref>
<ref id="bibr29-0272989X11398489">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ochnio</surname><given-names>JJ</given-names></name>
<name><surname>Scheifele</surname><given-names>DW</given-names></name>
<name><surname>Ho</surname><given-names>M</given-names></name>
</person-group>. <article-title>Hepatitis A virus infections in urban children—are preventive opportunities being missed?</article-title> <source>J Infect Dis</source>. <year>1997</year>;<volume>176</volume>(<issue>6</issue>):<fpage>1610</fpage>–<lpage>3</lpage>.</citation>
</ref>
<ref id="bibr30-0272989X11398489">
<label>30.</label>
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Ochnio</surname><given-names>JJ</given-names></name>
<name><surname>Scheifele</surname><given-names>DW</given-names></name>
<name><surname>Marion</surname><given-names>SA</given-names></name>
<name><surname>Bigham</surname><given-names>M</given-names></name>
<name><surname>Ho</surname><given-names>M</given-names></name>
</person-group>. <article-title>Hepatitis A virus (HAV) infections in young adults in British Columbia: feasibility of a novel mail-based approach to population sampling</article-title>. <conf-name>Proceedings of the 7th Annual Conference on Vaccine Research</conf-name>. <conf-loc>Arlington, VA</conf-loc>, <conf-date>January 1, 2001</conf-date>. <comment>Abstract P4</comment>.</citation>
</ref>
<ref id="bibr31-0272989X11398489">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McFarlane</surname><given-names>ES</given-names></name>
<name><surname>Embil</surname><given-names>JA</given-names></name>
<name><surname>Manuel</surname><given-names>FR</given-names></name>
<name><surname>Gorelick</surname><given-names>M</given-names></name>
</person-group>. <article-title>Prevalence of antibodies to hepatitis A antigen in patients attending a clinic for treatment of sexually transmitted diseases</article-title>. <source>Sex Transm Dis</source>. <year>1980</year>;<volume>7</volume>(<issue>2</issue>):<fpage>87</fpage>–<lpage>9</lpage>.</citation>
</ref>
<ref id="bibr32-0272989X11398489">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacobsen</surname><given-names>KH</given-names></name>
<name><surname>Koopman</surname><given-names>JS</given-names></name>
</person-group>. <article-title>The effects of socioeconomic development on worldwide hepatitis A virus seroprevalence patterns</article-title>. <source>Int J Epidemiol</source>. <year>2005</year>;<volume>34</volume>(<issue>3</issue>):<fpage>600</fpage>–<lpage>9</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>